The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.

/pdf/sunitinib-malate-for-the-treatment-of-pancreatic-2hutbwl0rl.pdf

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

This review of the role of platelets in atherothrombosis illuminates the surprisingly numerous activities of these tiny, anucleate cells and stresses their participation in the inflammatory component of atherothrombosis. The information is presented in the context of the prevention of atherothrombosis by antiplatelet agents now in clinical use.

/pdf/platelet-activation-and-atherothrombosis-4afsrhs7f0.pdf

Platelet Activation and Atherothrombosis

Platelets represent an important linkage between inflammation, thrombosis, and atherogenesis Inflammation is characterized by interactions among platelets, leukocytes, and ECs These interactions trigger autocrine and paracrine activation processes that lead to leukocyte recruitment into the vascular wall Platelet-induced chronic inflammatory processes at the vascular wall result in development of atherosclerotic lesions and atherothrombosis This Review highlights the molecular machinery and inflammatory pathways used by platelets to initiate and accelerate atherothrombosis

/pdf/platelets-in-inflammation-and-atherogenesis-7af82m36ay.pdf

Platelets in inflammation and atherogenesis

These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology, the Society for Endocrinology, the Association of Surgeons of Great Britain and Ireland (and its Surgical Specialty Associations), the British Society of Gastrointestinal and Abdominal Radiology and others. The authorship represents leaders of the various groups in the UK and Ireland Neuroendocrine Tumour Society, but a large amount of work has been carried out by other specialists, many of whom attended a guidelines conference in May 2009. We have attempted to represent this work in the acknowledgements section. Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments. However, there remain few randomised trials in the field and the disease is uncommon, hence all evidence must be considered weak in comparison with other more common cancers.

https://gut.bmj.com/content/gutjnl/61/1/6.full.pdf

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Departments of a Surgery and b Radiology, University of Verona, Verona , Italy; c Department of Internal Medicine, Charite, University of Berlin, Berlin , Germany; d Department of Nuclear Medicine, University of Rotterdam, Rotterdam , The Netherlands; e M. Korner, University of Bern, Institut fur Pathologie, Bern , Switzerland; f Department of Oncology, South Florida University, Tampa, Fla. , USA; g Department of Internal Medicine, Charite, University of Berlin, Berlin , Germany; h Department of Radiology, Charite Universitatsmedizin, Berlin , Germany; i Department of Surgery, Stadtisches Klinikum Neuss, Lukas Hospital, Neuss , Germany; j Department of Surgery, Zurich Hospital, Zurich , Switzerland; k Department of Surgery, Vivantes Humboldt Hospital, Berlin , Germany; l Department of Endocrine Oncology, University of Uppsala, Uppsala , Sweden; m Department of Pathology, University of Lyon, Lyon , France

Well-differentiated pancreatic nonfunctioning tumors/carcinoma.

Aspirin resistance has been recognised to occur in patients with cardiovascular disease and is associated with poor clinical prognosis. The purpose of the present study was to evaluate the prevalence of aspirin resistance in 172 patients with diabetes mellitus type 2 (DM-2). Platelet function of 172 consecutive patients with type 2 diabetes on chronic aspirin therapy was evaluated. The effect of aspirin was assessed using the platelet function analyser (PFA-100) system, reporting platelet-dependent thrombus formation as the time required to close a small aperture in a biologically active membrane. Resistance to aspirin was defined as a normal collagen/epinephrine-induced closure time (82–165 s). Aspirin responders were defined when closure time was ≥300 s. Thirty-seven (21.5%) of the type 2 diabetic patients were found to be resistant to chronic aspirin therapy, 29 (16.9%) were semi-responders and 106 (61.6%) were responders. Univariate analysis revealed that aspirin non-responders were significantly younger (p<0.05) compared to aspirin responders. A significant number of type 2 diabetic patients are resistant to aspirin therapy. Aspirin resistance can be evaluated by point-of-care testing and should be recognised in diabetic patients that are treated for primary or secondary prevention.

Prevalence of aspirin resistance in patients with type 2 diabetes.

Background— Platelets play a key role in atherogenesis and thromboembolic complications in patients with type 2 diabetes. Methods and Results— We prospectively examined the relationship between sys...

Ursula Plöckinger

Papers

Well-differentiated pancreatic nonfunctioning tumors/carcinoma.

Prevalence of aspirin resistance in patients with type 2 diabetes.

Platelet Degranulation Is Associated With Progression of Intima-Media Thickness of the Common Carotid Artery in Patients With Diabetes Mellitus Type 2

Stressechocardiography for risk stratification of asymptomatic patients with type 2 diabetes mellitus